PMC:7216760 / 21550-22046 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T112","span":{"begin":190,"end":198},"obj":"Disease"},{"id":"T113","span":{"begin":297,"end":305},"obj":"Disease"},{"id":"T114","span":{"begin":402,"end":410},"obj":"Disease"},{"id":"T115","span":{"begin":475,"end":483},"obj":"Disease"}],"attributes":[{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A114","pred":"mondo_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A115","pred":"mondo_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00224.Tables showing viral outbreaks since year 2000, different targets expressed in SARS-CoV-2 proteome, unique therapeutic interventions in recruiting and nonrecruiting clinical studies for COVID-19, and structures of select approved or investigational drugs tested for drug repurposing against SARS-CoV-2; structures of the novel inhibitors obtained from the PDB for SARS-CoV-2 Mpro (PDF)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T225","span":{"begin":366,"end":372},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00224.Tables showing viral outbreaks since year 2000, different targets expressed in SARS-CoV-2 proteome, unique therapeutic interventions in recruiting and nonrecruiting clinical studies for COVID-19, and structures of select approved or investigational drugs tested for drug repurposing against SARS-CoV-2; structures of the novel inhibitors obtained from the PDB for SARS-CoV-2 Mpro (PDF)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T192","span":{"begin":360,"end":365},"obj":"Chemical"},{"id":"T193","span":{"begin":377,"end":381},"obj":"Chemical"},{"id":"T194","span":{"begin":438,"end":448},"obj":"Chemical"}],"attributes":[{"id":"A192","pred":"chebi_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A193","pred":"chebi_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A194","pred":"chebi_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00224.Tables showing viral outbreaks since year 2000, different targets expressed in SARS-CoV-2 proteome, unique therapeutic interventions in recruiting and nonrecruiting clinical studies for COVID-19, and structures of select approved or investigational drugs tested for drug repurposing against SARS-CoV-2; structures of the novel inhibitors obtained from the PDB for SARS-CoV-2 Mpro (PDF)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T96","span":{"begin":0,"end":496},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00224.Tables showing viral outbreaks since year 2000, different targets expressed in SARS-CoV-2 proteome, unique therapeutic interventions in recruiting and nonrecruiting clinical studies for COVID-19, and structures of select approved or investigational drugs tested for drug repurposing against SARS-CoV-2; structures of the novel inhibitors obtained from the PDB for SARS-CoV-2 Mpro (PDF)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"635","span":{"begin":486,"end":490},"obj":"Gene"},{"id":"636","span":{"begin":190,"end":200},"obj":"Species"},{"id":"637","span":{"begin":402,"end":412},"obj":"Species"},{"id":"638","span":{"begin":475,"end":485},"obj":"Species"},{"id":"639","span":{"begin":297,"end":305},"obj":"Disease"}],"attributes":[{"id":"A635","pred":"tao:has_database_id","subj":"635","obj":"Gene:8673700"},{"id":"A636","pred":"tao:has_database_id","subj":"636","obj":"Tax:2697049"},{"id":"A637","pred":"tao:has_database_id","subj":"637","obj":"Tax:2697049"},{"id":"A638","pred":"tao:has_database_id","subj":"638","obj":"Tax:2697049"},{"id":"A639","pred":"tao:has_database_id","subj":"639","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00224.Tables showing viral outbreaks since year 2000, different targets expressed in SARS-CoV-2 proteome, unique therapeutic interventions in recruiting and nonrecruiting clinical studies for COVID-19, and structures of select approved or investigational drugs tested for drug repurposing against SARS-CoV-2; structures of the novel inhibitors obtained from the PDB for SARS-CoV-2 Mpro (PDF)"}